Patients with the BRCA1/2 mutation had the best response and longest median radiographic progression-free survival (rPFS) compared to patients with the 16 other gene mutations, but because olaparib did have an effect on these other mutations as well, this study supported the genomic stratification of mCRPC and olaparib’s potential in mCRPC patients with tumor gene aberrations besides the BRCA1/2 mutation. This evidence concerns the gene BRCA1 and neoplasm.